Canaccord raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $394 from $377 and keeps a Buy rating on the shares following the quarterly results and business highlights. Sales revenue for Rezdiffra, the company’s first FDA approved nonalcoholic steatohepatitis drug, has beat expectations in two sequential quarters, the analyst tells investors in a research note. The firm is highly confident that product sales revenue will achieve a fast growth rate in the coming quarters.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Madrigal Pharmaceuticals reports Q3 EPS ($4.92), consensus ($6.91)
- Madrigal Pharmaceuticals to present multiple resmetirom data presentations
- MDGL Upcoming Earnings Report: What to Expect?
- Madrigal Pharmaceuticals price target lowered to $350 from $375 at Oppenheimer
- 3 Best Stocks to Buy Now, 10/23/2024, According to Top Analysts